Skip to main content

Arne Östman's Group

The research aims at a better understanding of the paracrine interplay in the tumormicroenvironment between malignant cells, fibroblasts, vascular cells and immune cells. Particular attention is given to the roles of the PDGF system in this context. During the last years we have also identified other proteins, involved in this interplay, that affect tumor growth and metastasis.

Projects commonly integrate analyses using cell- and animal-models of cancer together with correlative profiling of clinical samples. Studies have been performed across a broad range of tumor types, including breast, prostate, ovarian, colorectal and kidney cancer. Since some years a distinct program on the tumor microenvironment of sarcoma is being headed by Monika Ehnman.

The group actively promotes studies taking advantage of the complementary expertise of biologists, pathologists and oncologists. A number of projects have been performed in collaboration with pharma companies.

Group members

Arne Östman, Professor, Group Leader
Monika Ehnman, PhD, Assistant Professor
Mercedes Herrera Torres, PhD, Postdoc
Lina Leiss, PhD, Postdoc
Pablo Moreno Ruiz, PhD, Postdoc (affiliated)
Sara Corvigno, MD, PhD
Wiem Chaabane, PhD, Postdoc
Alfonso Martin Barnabe, PhD, Postdoc
Magnus Frödin, MD, PhD (affiliated)
Alessandro Mega, PhD student
Artur Mezheyeuski, MD, PhD (affiliated)

Selected publications since 2013

23583284

23243022

23901112

24780757

Cancer-associated fibroblasts expressing CXCL14 rely upon NOS1-derived nitric oxide signaling for their tumor-supporting properties.
Augsten M, Sjöberg E, Frings O, Vorrink S, Frijhoff J, Olsson E, et al
Cancer Res. 2014 Jun;74(11):2999-3010

Glioma-induced inhibition of caspase-3 in microglia promotes a tumor-supportive phenotype.
Shen X, Burguillos M, Osman A, Frijhoff J, Carrillo-Jiménez A, Kanatani S, et al
Nat. Immunol. 2016 Nov;17(11):1282-1290

Expression of the chemokine CXCL14 in the tumour stroma is an independent marker of survival in breast cancer.
Sjöberg E, Augsten M, Bergh J, Jirström K, Östman A
Br. J. Cancer 2016 05;114(10):1117-24

Perivascular PDGFR-β is an independent marker for prognosis in renal cell carcinoma.
Frödin M, Mezheyeuski A, Corvigno S, Harmenberg U, Sandström P, Egevad L, et al
Br. J. Cancer 2017 Jan;116(2):195-201

Irreversible inhibition of cytosolic thioredoxin reductase 1 as a mechanistic basis for anticancer therapy.
Stafford W, Peng X, Olofsson M, Zhang X, Luci D, Lu L, et al
Sci Transl Med 2018 Feb;10(428):

A minority-group of renal cell cancer patients with high infiltration of CD20+B-cells is associated with poor prognosis.
Sjöberg E, Frödin M, Lövrot J, Mezheyeuski A, Johansson M, Harmenberg U, et al
Br. J. Cancer 2018 Oct;119(7):840-846

A Novel ACKR2-Dependent Role of Fibroblast-Derived CXCL14 in Epithelial-to-Mesenchymal Transition and Metastasis of Breast Cancer.
Sjöberg E, Meyrath M, Milde L, Herrera M, Lövrot J, Hägerstrand D, et al
Clin. Cancer Res. 2019 Mar;():

Impact of Epithelial-Stromal Interactions on Peritumoral Fibroblasts in Ductal Carcinoma in Situ.
Strell C, Paulsson J, Jin S, Tobin N, Mezheyeuski A, Roswall P, et al
J. Natl. Cancer Inst. 2019 Feb;():

Review articles

PDGF receptors in tumor stroma: Biological effects and associations with prognosis and response to treatment.
Östman A
Adv. Drug Deliv. Rev. 2017 11;121():117-123

Microvascular Mural Cells in Cancer.
Östman A, Corvigno S
Trends Cancer 2018 12;4(12):838-848

Full list of publications